Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTO NASDAQ:EVAX NASDAQ:GLTO NASDAQ:SHPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTOAltamira Therapeutics$0.30-25.9%$0.36$0.30▼$1.34$1.02M1.8291,465 shs753,013 shsEVAXEvaxion A/S$2.94+0.7%$2.82$1.20▼$16.68$4.10M0.1471,269 shs13,427 shsGLTOGalecto$2.75-2.8%$3.33$2.01▼$14.56$3.75M1.35248,189 shs30,891 shsSHPHShuttle Pharmaceuticals$3.58+3.2%$3.62$3.00▼$56.25$3.72M-1.0826,201 shs24,591 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTOAltamira Therapeutics0.00%0.00%0.00%0.00%-64.29%EVAXEvaxion A/S-0.68%-1.02%+1.39%+41.06%-80.53%GLTOGalecto-1.39%-8.41%-16.89%-10.61%-78.11%SHPHShuttle Pharmaceuticals-3.34%+3.58%+4.52%+0.58%-91.84%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTOAltamira Therapeutics$0.30-25.9%$0.36$0.30▼$1.34$1.02M1.8291,465 shs753,013 shsEVAXEvaxion A/S$2.94+0.7%$2.82$1.20▼$16.68$4.10M0.1471,269 shs13,427 shsGLTOGalecto$2.75-2.8%$3.33$2.01▼$14.56$3.75M1.35248,189 shs30,891 shsSHPHShuttle Pharmaceuticals$3.58+3.2%$3.62$3.00▼$56.25$3.72M-1.0826,201 shs24,591 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTOAltamira Therapeutics0.00%0.00%0.00%0.00%-64.29%EVAXEvaxion A/S-0.68%-1.02%+1.39%+41.06%-80.53%GLTOGalecto-1.39%-8.41%-16.89%-10.61%-78.11%SHPHShuttle Pharmaceuticals-3.34%+3.58%+4.52%+0.58%-91.84%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTOAltamira Therapeutics 0.00N/AN/AN/AEVAXEvaxion A/S 3.00Buy$10.00240.14% UpsideGLTOGalecto 3.00Buy$10.00263.64% UpsideSHPHShuttle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTOAltamira Therapeutics$320K3.19N/AN/A$4.56 per share0.07EVAXEvaxion A/S$3.34M1.23N/AN/A($1.18) per share-2.49GLTOGalectoN/AN/AN/AN/A$10.99 per shareN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/A$4.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTOAltamira Therapeutics-$4.31MN/A0.00N/AN/AN/AN/AN/AN/AEVAXEvaxion A/S-$10.57M-$1.32N/AN/AN/A-316.03%-319.52%-63.56%10/30/2025 (Estimated)GLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%11/7/2025 (Estimated)SHPHShuttle Pharmaceuticals-$9.15M-$4.15N/A∞N/AN/A-772.76%-347.06%N/ALatest CYTO, EVAX, SHPH, and GLTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025EVAXEvaxion A/S-$0.50-$0.76-$0.26-$0.76N/A$0.04 million8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTOAltamira TherapeuticsN/AN/AN/AN/AN/AEVAXEvaxion A/SN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/ASHPHShuttle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTOAltamira TherapeuticsN/A0.43N/AEVAXEvaxion A/S1.733.423.42GLTOGalectoN/A4.964.96SHPHShuttle PharmaceuticalsN/A3.073.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTOAltamira Therapeutics1.91%EVAXEvaxion A/S11.04%GLTOGalecto14.20%SHPHShuttle Pharmaceuticals4.58%Insider OwnershipCompanyInsider OwnershipCYTOAltamira Therapeutics13.03%EVAXEvaxion A/S41.64%GLTOGalecto10.80%SHPHShuttle Pharmaceuticals12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTOAltamira Therapeutics203.40 million2.96 millionNot OptionableEVAXEvaxion A/S601.40 million819,000No DataGLTOGalecto401.32 million1.18 millionOptionableSHPHShuttle Pharmaceuticals51.07 million936,000Not OptionableCYTO, EVAX, SHPH, and GLTO HeadlinesRecent News About These CompaniesShuttle Pharmaceuticals Appoints Adam Chambers as DirectorSeptember 8, 2025 | tipranks.comShuttle Pharmaceuticals Director Steven Richards ResignsSeptember 5, 2025 | tipranks.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 16, 2025 | finanznachrichten.deShuttle Pharma Provides Second Quarter 2025 Corporate UpdateAugust 14, 2025 | globenewswire.comShuttle Pharmaceuticals COO Resigns Amid Leadership ChangesJuly 30, 2025 | tipranks.comShuttle Pharmaceuticals Inc News (SHPH) - Investing.comJuly 2, 2025 | investing.comSHPH - Shuttle Pharmaceuticals Holdings Inc Key Metrics | MorningstarJune 28, 2025 | morningstar.comMShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-Market - MorningstarJune 26, 2025 | morningstar.comMSHPH - Shuttle Pharmaceuticals Holdings Inc News | MorningstarJune 26, 2025 | morningstar.comMShuttle Pharmaceuticals Secures $4.25M in Private PlacementJune 26, 2025 | msn.comShuttle Pharmaceuticals Announces Closing of $4.25 Million Private Placement Priced At-the-MarketJune 24, 2025 | globenewswire.comShuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-MarketJune 20, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings Inc trading halted, news pendingJune 14, 2025 | msn.comShuttle Pharmaceuticals says reverse stock split to become effective June 16June 13, 2025 | finance.yahoo.comShuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern TimeJune 12, 2025 | globenewswire.comShuttle Pharmaceuticals Holdings, Inc. Proposes 25-for-1 Reverse Stock Split to Comply with Nasdaq RequirementsJune 12, 2025 | quiverquant.comQShuttle Pharma Announces Proposed Reverse Stock Split as Part of Strategic Nasdaq Compliance InitiativeJune 12, 2025 | globenewswire.comShuttle Pharma Appoints George Scorsis Chairman of the Board of DirectorsJune 4, 2025 | globenewswire.comShuttle Pharmaceuticals slashes exec salaries by 70% as it fights to preserve cashMay 29, 2025 | bizjournals.comShuttle Pharmaceuticals Holdings, Inc.: Shuttle Pharma Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCYTO, EVAX, SHPH, and GLTO Company DescriptionsAltamira Therapeutics NASDAQ:CYTOAltamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase II/III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It also offers Bentrio, a drug-free nasal spray for protection against airborne viruses and allergens. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is based in Hamilton, Bermuda.Evaxion A/S NASDAQ:EVAX$2.94 +0.02 (+0.68%) Closing price 03:57 PM EasternExtended Trading$2.90 -0.04 (-1.19%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Galecto NASDAQ:GLTO$2.75 -0.08 (-2.83%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.02 (+0.91%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Shuttle Pharmaceuticals NASDAQ:SHPH$3.58 +0.11 (+3.17%) Closing price 03:59 PM EasternExtended Trading$3.74 +0.16 (+4.36%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers . The company is based in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
